Biomol Ther.  2016 Jul;24(4):380-386. 10.4062/biomolther.2015.154.

Inhibition of Wnt Signaling by Silymarin in Human Colorectal Cancer Cells

Affiliations
  • 1Department of Bioresource Sciences, Andong National University, Andong 36729, Republic of Korea. jjb0403@anu.ac.kr

Abstract

Silymarin from milk thistle (Silybum marianum) has been reported to show an anti-cancer activity. In previous study, we reported that silymarin induces cyclin D1 proteasomal degradation through NF-κB-mediated threonine-286 phosphorylation. However, mechanism for the inhibition of Wnt signaling by silymarin still remains unanswered. Thus, we investigated whether silymarin affects Wnt signaling in human colorectal cancer cells to elucidate the additional anti-cancer mechanism of silymarin. Transient transfection with a TOP and FOP FLASH luciferase construct indicated that silymarin suppressed the transcriptional activity of β-catenin/TCF. Silymarin treatment resulted in a decrease of intracellular β-catenin protein but not mRNA. The inhibition of proteasome by MG132 and GSK3β inhibition by SB216763 blocked silymarin-mediated downregulation of β-catenin. In addition, silymarin increased phosphorylation of β-catenin and a point mutation of S33Y attenuated silymarin-mediated β-catenin downregulation. In addition, silymarin decreased TCF4 and increased Axin expression in both protein and mRNA level. From these results, we suggest that silymarin-mediated downregulation of β-catenin and TCF4 may result in the inhibition of Wnt signaling in human colorectal cancer cells.

Keyword

Silymarin; Wnt signaling; Cancer chemoprevention; Human colorectal cancer

MeSH Terms

Colorectal Neoplasms*
Cyclin D1
Down-Regulation
Humans*
Luciferases
Milk Thistle
Phosphorylation
Point Mutation
Proteasome Endopeptidase Complex
RNA, Messenger
Silymarin*
Transfection
Cyclin D1
Luciferases
Proteasome Endopeptidase Complex
RNA, Messenger
Silymarin
Full Text Links
  • BT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr